Clinical Trial

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Phase 2 dose.
Protocol Amendment History 22 amendments
This ClinicalTrials.gov record has been amended 22 times since 2022-07-13; most recent amendment 2026-05-12.
Status change: Recruiting → Active, Not Recruiting 2024-06-13
Status change: Not Yet Recruiting → Recruiting 2022-08-16
Trial Details
NCT Number NCT05462717
Lead Sponsor Revolution Medicines, Inc.
Conditions Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
Enrollment 222 participants
Start Date 2022-09-19
Primary Completion 2027-03-31 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-15